- Home
- ELUT vs PBYI Comparison
ELUT vs PBYI Comparison
Compare ELUT & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELUT
- PBYI
- Stock Information
- Founded
- ELUT 2015
- PBYI 2010
- Country
- ELUT United States
- PBYI United States
- Employees
- ELUT N/A
- PBYI N/A
- Industry
- ELUT Medical Specialities
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- ELUT Health Care
- PBYI Health Care
- Exchange
- ELUT Nasdaq
- PBYI Nasdaq
- Market Cap
- ELUT 111.2M
- PBYI 126.5M
- IPO Year
- ELUT 2020
- PBYI N/A
- Fundamental
- Price
- ELUT $3.56
- PBYI $2.42
- Analyst Decision
- ELUT Strong Buy
- PBYI Strong Buy
- Analyst Count
- ELUT 2
- PBYI 1
- Target Price
- ELUT $10.00
- PBYI $7.00
- AVG Volume (30 Days)
- ELUT 38.2K
- PBYI 524.8K
- Earning Date
- ELUT 11-14-2024
- PBYI 11-07-2024
- Dividend Yield
- ELUT N/A
- PBYI N/A
- EPS Growth
- ELUT N/A
- PBYI 492.79
- EPS
- ELUT N/A
- PBYI 0.47
- Revenue
- ELUT $24,782,000.00
- PBYI $243,569,000.00
- Revenue This Year
- ELUT $9.65
- PBYI N/A
- Revenue Next Year
- ELUT $39.29
- PBYI N/A
- P/E Ratio
- ELUT N/A
- PBYI $5.20
- Revenue Growth
- ELUT N/A
- PBYI 6.30
- 52 Week Low
- ELUT $1.39
- PBYI $2.23
- 52 Week High
- ELUT $5.24
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- ELUT 46.89
- PBYI 36.08
- Support Level
- ELUT $3.57
- PBYI $2.83
- Resistance Level
- ELUT $4.02
- PBYI $3.25
- Average True Range (ATR)
- ELUT 0.26
- PBYI 0.29
- MACD
- ELUT 0.04
- PBYI -0.04
- Stochastic Oscillator
- ELUT 48.89
- PBYI 6.03
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.